Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Driving revenue growth and earnings growth are two different things.
Overview
Teva Pharmaceutical Industries (NYSE: TEVA) has clawed back from the brink like few drugmakers have. After a long stretch of poor performance, a company once buried under debt, patent cliffs, and litigation is now up by 97% in the last 12 months. The bull case credits its expanding biosimilars lineup, and that quickly growing segment could mean the stock has more room to run.
Still, a recently risen share price and a growing product line are not the same as a stock worth buying today. Will biosimilars truly move the needle for a business this size? Is the easy money already made, or is there more to come? Let's find out.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- Is it too late to buy SpaceX’s stock? Here’s how Tesla’s did after one day — and five years.
- Brent Oil Drops Below $90 as the U.S. Closes in on a Peace Deal With Iran. What it Means for Oil Stocks.
- Adobe’s CFO is departing for Marvell. And it’s one more reason for investors to choose chips over software.